Search

Your search keyword '"Reenaers, C."' showing total 228 results
Start Over Author "Reenaers, C."
228 results on '"Reenaers, C."'

4. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study

Author

Calmejane, L, primary, Reenaers, C, additional, Amiot, A, additional, Nuzzo, A, additional, Vuitton, L, additional, Altwegg, R, additional, Guillo, L, additional, Wils, P, additional, Roblin, X, additional, Le Cosquer, G, additional, Simon, M, additional, Benezech, A, additional, Laharie, D, additional, Fumery, M, additional, Buisson, A, additional, Charkaoui, M, additional, Nancey, S, additional, Sabra, G, additional, Geyl, S, additional, Coffin, B, additional, Cavicchi, M, additional, Le Berre, C, additional, Goutorbe, F, additional, Bouguen, G, additional, Vidon, M, additional, Christmann, P Y, additional, Kirchgesner, J, additional, and Uzzan, M, additional

Published
2024
Full Text
View/download PDF

5. P397 Distinct blood protein profiles associated with ileal and colonic ulcers in Crohn’s disease

Author

Pierre, N, primary, Huynh-Thu, V A, additional, Baiwir, D, additional, Vieujean, S, additional, Bequet, E, additional, Reenaers, C, additional, Van Kemseke, C, additional, Salée, C, additional, Massot, C, additional, Fléron, M, additional, Mazzucchelli, G, additional, Trzpiot, L, additional, Eppe, G, additional, De Pauw, E, additional, Louis, E, additional, and Meuwis, M, additional

Published
2024
Full Text
View/download PDF

6. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series

Author

Vieujean, S, Moens, A, Hassid, D, Rothfuss, K, Savarino, E, Vavricka, S R, Reenaers, C, Jacobsen, B, Allez, M, Ferrante, M, Rahier, Jean-François, ECCO CONFER investigators, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de gastro-entérologie

Subjects
inflammatory bowel disease, Gastroenterology, General Medicine, Pneumocystis jirovecii pneumonia
Abstract

Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy. Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.

Published
2022
Full Text
View/download PDF

8. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases

Author

Goessens, L., Colombel, J. -F., Outtier, A., Ferrante, M., Sabino, J., Judge, C., Saeidi, R., Rabbitt, L., Armuzzi, A., Domenech, E., Michalopoulos, G., Cremer, A., Garcia-Alonso, F. J., Molnar, T., Karmiris, K., Gecse, K., Van Oostrom, J., Lowenberg, M., Farkas, K., Atreya, R., Ribaldone, D. G., Selinger, C., Hoentjen, F., Bihin, B., Sebastian, S., Rahier, J. -F., Baert, F., Horin, S. B., Bossuyt, P., Mas, E. B., Buckley, M., Byron, C., Coe, C., Doherty, G. A., Dragoni, G., Fernandes, S., Gaya, D. P., Gleeson, S., Keogh, A., Levine, A., Ortega, T. L., Lobo, A. J., Macken, E., Mccarthy, J., Noor, N., O'Toole, A., Posen, A., Privitera, G., Pugliese, D., Raine, T., Reenaers, C., Resal, T., Scarcelli, A., Slattery, E., Strubbe, B., Sugrue, K., Groen, M. T., Vicente, G. T., Truyens, M., Viola, A., Yanai, H., Zulquernain, S. A., Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Unité de support scientifique

Subjects
Adult, Male, safety, medicine.medical_specialty, Combination therapy, Adolescent, Opportunistic infection, Inflammatory bowel disease, combination therapy, Young Adult, Interquartile range, inflammatory bowel disease, Internal medicine, Medicine, Humans, biologics, Adverse effect, Retrospective Studies, Biological Products, treatment, business.industry, immune mediated inflammatory disease, Gastroenterology, Retrospective cohort study, medicine.disease, Inflammatory Bowel Diseases, Europe, small molecules, Oncology, Immune-mediated inflammatory diseases, Original Article, Drug Therapy, Combination, Female, Skin cancer, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

BACKGROUND AND AIMS: Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. METHODS: Combination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the occurrence of serious infection, opportunistic infection, hospitalisation, life-threatening event, worsening of IBD or immune-mediated inflammatory diseases (IMID), cancer and death. Efficacy was evaluated as the physician global assessment of the combination and comparison of clinical/endoscopic scores of IBD/IMID activity prior and during combination. RESULTS: A total of 104 combinations were collected in 98 patients. Concomitant IMID were present in 41 patients. Reasons for starting combination therapy were active IBD (67%), active IMID or extra-intestinal manifestations (EIM) (22%), both (10%) and unclassified in 1. Median duration of combination was 8 months (interquartile range 5-16). During 122 patient-years of follow-up, 42 significant adverse events were observed, mostly related to uncontrolled IBD. There were 10 significant infections, 1 skin cancer and no death. IBD disease activity was clinically improved in 70% and IMID/EIM activity in 81% of the patients. Overall, combination was continued in 55% of the patients. CONCLUSIONS: Combination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%. ispartof: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL vol:9 issue:10 pages:1136-1147 ispartof: location:England status: published

Published
2021
Full Text
View/download PDF

10. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

Author

Le Cosquer, G, primary, Gilletta, C, additional, Amiot, A, additional, Rivière, P, additional, Nachury, M, additional, Rouillon, C, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Fumery, M, additional, Savoye, G, additional, Biron, A, additional, Picon, L, additional, Peyrin-Biroulet, L, additional, Vidon, M, additional, Reenaers, C, additional, Simon, M, additional, Caron, B, additional, Serrero, M, additional, Altwegg, R, additional, Benezech, A, additional, Goutorbe, F, additional, Rahier, J F, additional, Beaugerie, L, additional, Pelletier, A L, additional, Caillo, L, additional, Laharie, D, additional, and Poullenot, F, additional

Published
2023
Full Text
View/download PDF

12. Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Author

Van de Vondel, Saartje, Baert, Filip, Reenaers, Christine, Vanden Branden, Stijn, Amininejad, Leila, Dewint, Pieter, Van Moerkercke, Wouter, Rahier, Jean-François, Hindryckx, Pieter, Bossuyt, Peter, Ferrante, Marc, Baert, F, De Wulf, D, Moortgat, L, De Cock, E, Decaestecker, L, D’Hondt, A, Van Moerkercke, W, Himpe, S, Dewint, P, Reenaers, C, Van Kemzeke, C, Louis, E, Rahier, J F, Amininejad, L, Franchimont, D, Wambacq, V, Bossuyt, P, Van de Schoot, I, Asnong, K, Vanden Branden, S, Sterckx, A, Hindryckx, P, De Vos, M, Ferrante, M, Noman, M, Vermeire, S, Van Assche, G, Franchimont, D, Rahier, J -F, Ferrante, M, and Vermeire, S

Published
2018
Full Text
View/download PDF

15. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

16. How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C, Treton, X, Altwegg, R, Reenaers, C, Amiot, A, Fumery, Mathurin, Vuitton, L, Peyrin-Biroulet, L, Bouguen, G, Dewit, O, Nancey, S, Caillo, L, Roblin, X, Beylot-Barry, M, Rivière, P, Laharie, D, CHU Bordeaux [Bordeaux], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU Henri Mondor [Créteil], Chirurgie digestive [CHU Amiens], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)

Subjects
inflammatory bowel disease, [SDV]Life Sciences [q-bio], skin lesions, anti-TNF
Abstract

International audience; Background and aims - Optimal management of patients with inflammatory bowel disease [IBD] after anti-tumour necrosis factor [TNF] discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect. Methods - We conducted a multicentre retrospective study including consecutive IBD patients who discontinued anti-TNF due to severe induced skin lesions. Our objectives were to determine factors associated with dermatological remission [complete disappearance of skin lesions] and with IBD relapse in patients with inactive disease at inclusion, notably the impact of an early switch to another biological agent within 3 months of anti-TNF discontinuation. Results - Among the 181 patients [134 women, 160 Crohn's disease] included in the 13 participating centres, dermatological remission occurred in 110 [62%] patients with a median [interquartile range, IQR] interval of 8.0 [6.8-11.0] months. Scalp location was independently associated with less remission of skin lesions (hazard ratio [HR] = 0.64 [95% CI 0.43-0.94], p = 0.02) while early switch was independently associated with a higher probability of remission of skin lesions (HR = 1.64 [95% CI 1.1-2.5], p = 0.02). Among the 148 patients with inactive IBD at inclusion, disease relapse occurred in 75 [51%] patients with a median [IQR] interval of 26.0 [23.0-39.1] months. Survival rates without IBD relapse at 1 year were 85.8% [95% CI 77.5-94.9] in the early switch group and 59.3% [95% CI 48.9-71.9] in the other group [p

Published
2022
Full Text
View/download PDF

17. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE).

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Reenaers, C, Cremer, A, Dewit, O, De Vroey, B, Van Moerkercke, W, Bossuyt, P, Muls, V, Imschoot, J, Block, S, Hantson, A, Van Hootegem, P, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Reenaers, C, Cremer, A, Dewit, O, De Vroey, B, Van Moerkercke, W, Bossuyt, P, Muls, V, Imschoot, J, Block, S, Hantson, A, and Van Hootegem, P

Abstract

Vedolizumab (VDZ) is a gutselective integrin inhibitor used to treat Crohn's disease (CD) and ulcerative colitis (UC). This retrospective study assessed effectiveness and treatment persistence of VDZ in a Belgian reallife cohort of CD and UC patients. CD and UC patients from 15 Belgian centers, who started VDZ between 01/09/2015 and 31/06/2016 and attended ≥1 visit after the first VDZ infusion, were included. Data were collected before first infusion, at week (W)10, W14 (CD patients only), month (M)6 and last follow-up. Treatment response and remission rates (changes in disease activity scores) and treatment persistence (Kaplan-Meier analysis) were assessed. Of the 348 patients receiving at least one dose of VDZ, 325 (202 CD, 45 biologic-naïve; and 123 UC, 42 biologic-naïve) patients were included in data analyses. At M6, 87.6% (176/201) of CD and 86.1% (105/122) of UC patients were still on VDZ treatment, 75.6% (34/45) and 83.9% (26/31) achieved clinical response, and 66.7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naïve versus biologic-failure CD patients. VDZ offers an effective treatment option in real-life settings and treatment effectiveness appears higher in biologic-naïve versus biologic-failure CD patients. (Acta gastroenterol. belg., 2020, 83, 15-23).

Published
2022

18. Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease - A case series.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Vieujean, S, Moens, A, Hassid, D, Rothfuss, K, Savarino, E, Vavricka, S R, Reenaers, C, Jacobsen, B, Allez, M, Ferrante, M, Rahier, Jean-François, ECCO CONFER investigators, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de gastro-entérologie, Vieujean, S, Moens, A, Hassid, D, Rothfuss, K, Savarino, E, Vavricka, S R, Reenaers, C, Jacobsen, B, Allez, M, Ferrante, M, Rahier, Jean-François, and ECCO CONFER investigators

Abstract

Pneumocystis jirovecii pneumonia (PJP) is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease (IBD). Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP. PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organization. Clinical data were provided through a case report form. 18 PJP episodes were reported in 17 IBD patients (10 ulcerative colitis and 7 Crohn's disease). The median age on PJP diagnosis was 55 years (IQR, 40-68 years). Two PJP (11.1%) occurred in patients on triple immunosuppression, 10 patients (55.6%) had double immunosuppressive treatment, 4 patients (22.2%) had monotherapy and 2 PJP occurred in absence of immunosuppressive treatment (one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation). Immunosuppressive therapies included steroids (n=12), thiopurines (n=10), infliximab (n=4), ciclosporin (n=2), methotrexate (n=1) and tacrolimus (n=1). None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulfamethoxazole or atovaquone and an ICU stay was required in 7 cases. Two patients (aged 71 and 32 years) died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others. This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.

Published
2022

21. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study

Author

Cottron, C, primary, Treton, X, additional, Altwegg, R, additional, Reenaers, C, additional, Amiot, A, additional, Fumery, M, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Bouguen, G, additional, Dewit, O, additional, Nancey, S, additional, Caillo, L, additional, Roblin, X, additional, Beylot-Barry, M, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

22. Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C., Treton, X., Altwegg, R., Reenaers, C., Amiot, A., Fumery, Mathurin, Vuitton, L., Peyrin-Biroulet, L., Bouguen, G., Dewit, O., Nancey, S., Caillo, L., Roblin, X., Beylot-Barry, M., Riviere, P., Laharie, D., CHU Bordeaux [Bordeaux], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHI Créteil, CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Universitaire de Nancy (CHU Nancy), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022
Full Text
View/download PDF

23. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Author

Sallette, M, primary, Bouhnik, Y, additional, Nachury, M, additional, Bellanger, C, additional, Laharie, D, additional, Amiot, A, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Altwegg, R, additional, Buisson, A, additional, Reenaers, C, additional, Bouguen, G, additional, Vuitton, L, additional, Bourreille, A, additional, Gilletta, C, additional, Serrero, M, additional, Hébuterne, X, additional, and Filippi, J, additional

Published
2022
Full Text
View/download PDF

25. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

26. P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Author

Cottron, C, primary, Treton, X, additional, Altwegg, R, additional, Reenaers, C, additional, Amiot, A, additional, Fumery, M, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Bouguen, G, additional, Dewit, O, additional, Nancey, S, additional, Caillo, L, additional, Roblin, X, additional, Beylot-Barry, M, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

30. Effectiveness and persistence of Vedolizumab in patients with inflammatory bowel disease : results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)

Author

Reenaers, C., Cremer, A., Dewit, O., Vroey, B., Moerkercke, W., peter bossuyt, Muls, V., Imschoot, J., Block, S., Hantson, A., Hootegem, P., UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie

Subjects
vedolizumab, Remission Induction, effectiveness, Antibodies, Monoclonal, Humanized, Inflammatory Bowel Diseases, treatment predictors, Belgium, Gastrointestinal Agents, inflammatory bowel disease, Humans, real-life, treatment persistence, Retrospective Studies
Abstract

Vedolizumab (VDZ) is a gutselective integrin inhibitor used to treat Crohn's disease (CD) and ulcerative colitis (UC). This retrospective study assessed effectiveness and treatment persistence of VDZ in a Belgian reallife cohort of CD and UC patients. CD and UC patients from 15 Belgian centers, who started VDZ between 01/09/2015 and 31/06/2016 and attended ≥1 visit after the first VDZ infusion, were included. Data were collected before first infusion, at week (W)10, W14 (CD patients only), month (M)6 and last follow-up. Treatment response and remission rates (changes in disease activity scores) and treatment persistence (Kaplan-Meier analysis) were assessed. Of the 348 patients receiving at least one dose of VDZ, 325 (202 CD, 45 biologic-naïve; and 123 UC, 42 biologic-naïve) patients were included in data analyses. At M6, 87.6% (176/201) of CD and 86.1% (105/122) of UC patients were still on VDZ treatment, 75.6% (34/45) and 83.9% (26/31) achieved clinical response, and 66.7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naïve versus biologic-failure CD patients. VDZ offers an effective treatment option in real-life settings and treatment effectiveness appears higher in biologic-naïve versus biologic-failure CD patients. (Acta gastroenterol. belg., 2020, 83, 15-23).

Published
2020

33. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. (Inflammatory Bowel Disease)

Author

Louis, E., Michel, V., Hugot, J.P., Reenaers, C., Fontaine, F., Delforge, M., Yafi, F. El, Colombel, J.F., and Belaiche, J.

Subjects
Crohn's disease -- Development and progression -- Physiological aspects, Health, Physiological aspects, Development and progression
Abstract

Background: Crohn's disease is a heterogeneous entity. Disease behaviour, characterised as stricturing, penetrating, or non-stricturing non-penetrating, is a clinically important phenotype as it is associated with complications and need far [...]

Published
2003

40. Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B., Peyrin-Biroulet, L., Nachury, M., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Boureille, A., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., Fumery, Mathurin, Reymond, M., Bronowicki, J. P., Reimund, J. -M., Amiot, A., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Gastroenterology and Hepatology, University Medical Centre, Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], CHU Henri Mondor [Créteil], Institut des Sciences de la Terre de Paris (iSTeP), Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Henri Mondor, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

41. P286 Bariatric surgery in inflammatory bowel disease: outcome and safety from a GETAID registry population

Author

Reenaers, C, primary, Nachury, M, additional, Stefanescu, C, additional, Pineton de Chambrun, G, additional, Laharie, D, additional, Boileve, J, additional, Viennot, S, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Grimaud, J-C, additional, Bouguen, G, additional, Nahon, S, additional, Goutorbe, F, additional, and Coffin, B, additional

Published
2019
Full Text
View/download PDF

43. Autoimmune pancreatitis associated with inflammatory bowel disease: a multicentric study of the GETAID

Author

Lorenzo, D., Maire, F., Stefanescu, C., Gornet, J. M., Seksik, P., Grimaud, J. C., Bournet, B., Marteau, P., Amiot, Audrey, Laharie, D., Trang, C., Coffin, B., Bellaiche, G., Cadiot, G., Reenaers, C., Racine, A., Viennot, S., Pauwels, A., Bouguen, G., Savoye, G., Pelletier, A. L., de Pineton Chambrun, G., Lahmek, P., Nahon, S., Abitbol, V, Service de gastroentérologie, MICI et assistance nutritive, pôle des maladies de l’appareil digestif, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Géoazur (GEOAZUR 6526), Institut de Recherche pour le Développement (IRD)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Hôpital Robert Debré, Service d'Hépato-gastroentérologie, 51092 Reims, France, affiliation inconnue, Foie, métabolismes et cancer, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), ONERA - The French Aerospace Lab [Palaiseau], ONERA-Université Paris Saclay (COmUE), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Recherche pour le Développement (IRD)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting Abstract: P256

Published
2016
Full Text
View/download PDF

44. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B, primary, Peyrin-Biroulet, L, additional, Nachury, M, additional, Bouhnik, Y, additional, Seksik, P, additional, Bouguen, G, additional, Caillo, L, additional, Laharie, D, additional, Carbonnel, F, additional, Altwegg, R, additional, Reenaers, C, additional, Serrero, M, additional, Boureille, A, additional, Nancey, S, additional, Filippi, J, additional, Abitbol, V, additional, Savoye, G, additional, Vuitton, L, additional, Viennot, S, additional, Fumery, M, additional, Reymond, M, additional, Bronowicki, J P, additional, Reimund, J -M, additional, and Amiot, A, additional

Published
2018
Full Text
View/download PDF

48. Development of a small bowel capsule endoscopic index of severity in patients with Crohn's disease

Author

Bourreille, A., Attar, A., Maunoury, V., Simon, M., Aubourg, A., Fumery, Mathurin, Reimund, J. -M., Reenaers, C., Nion-Larmurier, I., Bonaz, B., Filippi, J., Dewit, O., Dray, X., Moreau, J., Altwegg, R., Roblin, X., Stefanescu, C., Mary, J. -Y., Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), CIC - Nantes, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Aboubekr Belkaid - University of Belkaïd Abou Bekr [Tlemcen], Hôpital Claude Huriez [Lille], CHU Lille, Service de Réanimation Médicale Sud, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU de Tours), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Grenoble, Cliniques Universitaires Saint-Luc [Bruxelles], Service de Gastroentérologie [CHU Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet - Saint-Étienne (UJM), Service de gastroentérologie, MICI et assistance nutritive, pôle des maladies de l’appareil digestif, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP]

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

50. Small bowel metastases from melanoma: does videocapsule provide additional information after FDG positron emission tomography?

Author

Ma Aerts, Fazia Mana, Bart Neyns, Looze, D., Reenaers, C., Daniel Urbain, Internal Medicine Specializations, Laboratory of Molecular and Medical Oncology, and Liver Cell Biology

Subjects
melanoma, metastases
Abstract

Finding small bowel metastases of melanoma can be important because surgical removal of unique small bowel metastasis of melanoma could improve survival. In this study, we evaluated if capsule endoscopy provides additional information after Pet CT has been performed. In this series of 9 patients collected from 3 university centers, capsule endoscopy influenced the therapeutic decision (to perform or not a surgical segmental resection) in 2/9 patients. All metastatic lesions were found in the proximal bowel. Capsule identified jejunum metastases in one case while Pet CT was negative, and identified metastases while Pet CT result was not conclusive. In one case PET CT identified mesenteric metastases while capsule was negative. SBCE influenced therapeutic decision in 2/9 patients concerning the decision of performing small bowel resection or not. In 1 patient SBCE changed the stage of the disease without affecting medical therapeutic strategy. The prognosis of patients with positive PET and/or capsule findings is very limited (2/3 died within the year). In selected patients, capsule endoscopy can provide complementary information once PET CT has been performed.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results